BR0210060A - Heterobicycles fkbp ligands - Google Patents

Heterobicycles fkbp ligands

Info

Publication number
BR0210060A
BR0210060A BR0210060-6A BR0210060A BR0210060A BR 0210060 A BR0210060 A BR 0210060A BR 0210060 A BR0210060 A BR 0210060A BR 0210060 A BR0210060 A BR 0210060A
Authority
BR
Brazil
Prior art keywords
fkbp
heterobicycles
fkbp ligands
ligands
heterobicyc
Prior art date
Application number
BR0210060-6A
Other languages
Portuguese (pt)
Inventor
Xinjun Hou
Nancy Sue Barta
Raymond Andrew Hudack
Liming Dong
Chuangxing Guo
Judith Gail Deal
Steven Lee Bender
Christopher Franklin Bigge
Lorraine Kathleen Fay
Corinne E Augelli-Szafran
Bradley William Caprathe
Arindam Chatterjee
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of BR0210060A publication Critical patent/BR0210060A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"LIGANDOS DE FKBP DE HETEROBICICLOS". Derivados de diazabiciclo[3.3.1]nonano que inibem a atividade de enzima de isomerase de peptidil-prolila associada com as proteínas de ligação de FK-506 (FKBP) são descritos para tratar distúrbios neurológicos. São também descritos compostos úteis para a preparação de tais inibidores."HETEROBICYC FKBP LINKS". Diazabicyclo [3.3.1] nonane derivatives that inhibit peptidyl prolyl isomerase enzyme activity associated with FK-506 binding proteins (FKBP) are described to treat neurological disorders. Also useful compounds for the preparation of such inhibitors are described.

BR0210060-6A 2001-05-10 2002-05-10 Heterobicycles fkbp ligands BR0210060A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28982801P 2001-05-10 2001-05-10
PCT/US2002/014966 WO2002089806A1 (en) 2001-05-10 2002-05-10 Heterobicycles fkbp-ligands

Publications (1)

Publication Number Publication Date
BR0210060A true BR0210060A (en) 2004-08-17

Family

ID=23113278

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210060-6A BR0210060A (en) 2001-05-10 2002-05-10 Heterobicycles fkbp ligands

Country Status (6)

Country Link
EP (1) EP1423119A4 (en)
JP (1) JP2004532854A (en)
BR (1) BR0210060A (en)
CA (1) CA2446795A1 (en)
MX (1) MXPA03010255A (en)
WO (1) WO2002089806A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024651A2 (en) * 2005-08-19 2007-03-01 Elan Pharmaceuticals, Inc. Bridged n-bicyclic sulfonamido inhibitors of gamma secretase
EP2690102A1 (en) * 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
EP2899192A1 (en) * 2014-01-24 2015-07-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
US9914732B2 (en) * 2014-01-24 2018-03-13 Max-Planck-Gesellschaft Zur Forderung Der Wissensc Haften E.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders
CA2953040A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders
US10597378B2 (en) 2017-09-08 2020-03-24 National Health Research Institutes Tetrahydroisoquinolines for use as MOR/NOP dual agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880927A (en) * 1972-06-19 1975-04-29 Lilly Co Eli {62 -Phenyl-{62 ,{62 -difluoroethylamines
AP2001002052A0 (en) * 1998-07-17 2001-03-31 Agouron Pharma Compounds, compositions, and methods for stimulating neuronal growth and elongation
US6818643B1 (en) * 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
HUP0301442A3 (en) * 2000-10-19 2007-03-28 Pfizer Prod Inc Bridged piperazine derivatives and pharmaceutical compositions containing them
WO2002060894A2 (en) * 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa

Also Published As

Publication number Publication date
EP1423119A4 (en) 2005-04-13
JP2004532854A (en) 2004-10-28
EP1423119A1 (en) 2004-06-02
CA2446795A1 (en) 2002-11-14
WO2002089806A1 (en) 2002-11-14
MXPA03010255A (en) 2005-03-07

Similar Documents

Publication Publication Date Title
ES2131457A1 (en) Small molecule inhibitors of rotamase enzyme activity
NO20021783L (en) Alkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
ES2194596A1 (en) Inhibitors of rotamase enzyme activity
MA27933A1 (en) INHIBITORS OF AKT ACTIVITY
NO20021781D0 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
EA199800329A1 (en) INHIBITORS OF ROTAMIC ENZYMATIVE ACTIVITY
NO992960D0 (en) Substituted nitrogen-containing heterocyclic compounds as inhibitors of p38 protein kinase
NZ508838A (en) Heterocyclic compounds as inhibitors of rotamase enzymes
BR9611624A (en) Cyclofilin Rotamase Activity Inhibitors
EA200100992A1 (en) IMPDH ENZYME INHIBITORS
DK0966465T3 (en) Inhibitors of IMPDH enzymes
IL165434A0 (en) Compounds having DPP-IV inhibitory activity
EA200870048A1 (en) Heteroaryl-PYRROLO [2,3-b] PYRIDINES AND PYRROLO [2,3-b] PYRMIDINES AS A INHIBITOR JANUS-KINASE INHIBITORS
EP0876387A4 (en) Method to improve the biological and antiviral activity of protease inhibitors
EA200100588A1 (en) PIPERIDINES AS CCR5 MODULATORS
WO2000043373A3 (en) Kinase inhibitors
HUP0002974A2 (en) N-linked sulfonamides of heterocyclic thioesters, process for producing them and pharmaceutical compositions containing them
UA66865C2 (en) Indenopyrrolocarbazoles, pharmaceutical composition, method for inhibiting kinase activity and method for treatment (variants)
UY27606A1 (en) PHOSPHARASE INHIBITORS
EP0313847A3 (en) Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents
BR0210060A (en) Heterobicycles fkbp ligands
WO2001016300A3 (en) Method of identifying inhibitors of cdc25
AU2001271611A1 (en) Oxindole derivatives
PL1628979T3 (en) Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
ES2170628A1 (en) Small molecule inhibitors of rotamase enzyme activity

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE 7A., E 8A., ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.